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In the past decade, our increased elucidation of the molecular basis of cancer has led to the development of novel targeted strategies for specific inhibition of cancer signaling
pathways that control growth, proliferation, apoptosis, and angiogenesis. Several monoclonal-antibody-based therapeutics
and small-molecule drugs have received clearance for use as
human therapeutics [1]. However, among these successes are
many candidate drugs that have failed in clinical trials despite
promising preclinical results [2].
The development of targeted therapeutics is expensive and
time consuming. In their Critical Path Initiative, the United
States Food and Drug Administration emphasized the need for
more effective tools to facilitate the rapid development of improved cancer therapeutics. One such tool is the use of targeted molecular optical imaging probes or contrast agents to
visualize the underlying processes in cancer.
Optical imaging, also known as molecular imaging, is a
rapidly developing field of research aimed at noninvasively
interrogating animals for disease progression, evaluating the
effects of a drug, assessing the pharmacokinetic behavior of
a drug, or identifying molecular biomarkers of disease. A prerequisite of molecular imaging is the development of specific, targeted imaging contrast agents to assess these biological processes. Several optical aids have shown great utility
in animal studies, including bioluminescence, fluorescent proteins, and fluorochrome-labeled agents. However, only the latter have the advantage of being potentially relevant to human
clinical applications.
The complexity of developing robust fluorochrome-labeled optical agents is often underestimated. Many studies describe the use of these agents, but guidelines for their development and testing are not readily available. The purpose of
this review is to outline some of the considerations for developing and using fluorochrome-labeled optical contrast agents
in animals. For simplicity, we have focused on the use of or-

ganic fluorochromes as labeling agents. These types of probes
are generally the most straightforward to develop and have
the greatest potential for translation to human clinical use.
Nanoparticles such as quantum dots, while useful for some
animal studies, are hampered by clearance issues and toxicity
and will not be specifically discussed. However, the principles
described here are generally applicable to any fluorescent optical imaging agent.
Principles of fluorescence imaging
The use of fluorochrome-labeled optical agents such as labeled antibodies, receptor-binding ligands, small molecules, peptides, and activatable probes offers a flexible and direct imaging methodology. The fluorescent labels
can be visualized by excitation with an appropriate light
source and capture of the emitted photons with a chargecoupled device camera or other optical detector. Several commercially available imaging systems enable visualization of these probes in mice. These include systems
from LI-COR Biosciences (http://www.licor.com/), CRI
(http://www.cri-inc.com/), Kodak (http://www.kodak.com/),
and Xenogen (http://www.xenogen.com/).
In fluorescent imaging, there are generally three parameters used to characterize the interaction of photons with tissues: light absorption, light scattering, and fluorescent emission. One of the most important considerations in optical
imaging is maximizing the depth of tissue penetration. Absorption and scattering of light are largely a function of the
wavelength of the excitation source [3]. Light is absorbed by
endogenous chromophores found in living tissue, including
hemoglobin, melanin, and lipid [3], [4], [5], [6], and [7]. In
general, light absorption and scattering decrease with increasing wavelength. Below ~700 nm, these effects result in shallow penetration depths of only a few millimeters [3]. Thus, in
1
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the visible region of the spectrum, only superficial assessment
of tissue features is possible. Above 900 nm, water absorption
can interfere with signal-to-background ratio. Because the absorption coefficient of tissue is considerably lower in the near
infrared (NIR) region (700–900 nm), light can penetrate more
deeply, to depths of several centimeters [3], [4], [5] and [6].
Fluorochromes with emissions in the NIR are not hindered by
interfering autofluorescence, so they tend to yield the highest
signal-to-background. The combination of increased depth of
penetration and reduced autofluorescence makes NIR fluorochromes ideally suitable for optical imaging in small animals
and potentially in humans also (Figure 1).
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Table 1.
Excitation and emission maxima of fluorescent dyes commonly used
for optical imaging

Near infrared fluorochromes
A key to enabling optical imaging has been the development
of suitable NIR fluorochromes. Important criteria for effective
optical imaging fluorochromes include excitation and emission maxima in the NIR between 700 and 900 nm, high quantum yield [3], [4], [5], [6] and [7], chemical and optical stability, and suitable pharmacological properties including aqueous
solubility, low nonspecific binding, rapid clearance of the free
dye, and low toxicity. The dyes most commonly used for fluorescent optical imaging are listed in Table 1.
The cyanine dye Cy5.5 has been used frequently for in vivo
imaging. The excitation/emission maxima (675 nm/695 nm)
are close to the NIR region, yielding acceptable signal-tobackground. Other dyes with excitation and emission maxima
in this region include IRDye 700DX, IRDye 680, Alexa Fluor
700, and Alexa Fluor 680. Although excitation and emission
wavelengths of these dyes are maximal in the more favorable red region, they do not give the optimal performance that
can be achieved by moving farther into the NIR. Thus they
are best used in situations when the highest sensitivity is not

required. However, the pthalocyanine dye IRDye 700DX has
properties that may make it attractive for imaging. IRDye
700DX is considerably less sensitive to photobleaching than
many organic fluorochromes; Peng et al. [8] have shown that
IRDye700DX is 100 times more photostable than Alexa Fluor
680 and Cy5.5. In addition, members of the pthalocyanine dye
class have been used for photodynamic therapy in the treatment of several types of cancer[9]. The photodynamic characteristics relevant to tumor therapy require prolonged exposure to the light source and therefore would not interfere with
tumor biology during the short exposures used for imaging.
Therefore, pthalocyanines have the potential to serve not only
as imaging agents but also as therapeutics.
The most widely used dyes with true NIR character include IRDye 800CW, Cy7, and Alexa Fluor 750. The excitation/emission ranges for these dyes are shown schematically
in Figure 1. In particular, IRDye 800CW has excitation/emission maxima of 774 nm/789 nm, which are centered at the
optimal wavelength for in vivo imaging. This dye has been
shown to be superior in performance to Cy5.5 with regard to
signal-to-background [10].
Targets and ligands

Figure 1. Schematic representation of the region of optimal signal-to-background ratio in tissue. Hemoglobin can interfere below
700 nm while water interferes above 900 nm. The excitation and
emission regions for several dyes commonly used in optical imaging
are also indicated.

Many targeted optical probes have been described in the literature. Targets include cell surface receptors, metabolic pathways, hormone receptors, apoptotic markers, and enzymatic
activities [11]. High-affinity probes may be developed by rational investigation, combinatorial chemical synthesis, or
phage display. An effective agent reaches the target at a sufficient concentration and/or is retained there for a sufficient
length of time to be visible at the time of imaging. Obstacles
such as rapid excretion, metabolism, nonspecific binding, and
physical barriers to the agent reaching the target must be overcome for a targeted optical agent to function robustly.
Delivery barriers present the greatest obstacle but can be
circumvented. One approach is to take advantage of normal
cellular transport and endocytic processes by targeting surface
receptors or transport pathways that internalize the optical
agent. Growth factor receptors are an example in which the
binding of a fluorochrome-labeled agent stimulates internal-
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ization via endocytosis. This has the added benefit of amplifying the fluorescent signal, since the fluorochrome will accumulate in the target cells. A second approach is to incorporate
a peptide membrane translocation signal into the optical agent
such that active transport of the imaging agent across the cell
membrane results. Signal peptides such as the HIV tat peptide
have been successfully used to transport nanoparticles into
cells [12].
Nonspecific binding is another critical issue for noninvasive tumor imaging. In vivo, the inability to eliminate unbound ligand can cause low signal-to-background. In addition, nonspecific binding or retention of the optical probe will
yield false positive results. Careful assessment of the optical
agent clearance pattern and verification of specific signals by
competition experiments can address this issue.
Antibody conjugates
Many of the first fluorochrome-conjugated targeted imaging agents were antibodies. For example, indocyanine-conjugated monoclonal antibodies against cells derived from a
squamous cell carcinoma have been used to image A431 cell
xenografts in nude mice [13]. Detection of the xenografts
was sensitive and specific. Cy3-, Cy5-, and Cy5.5-conjugated monoclonal antibodies have been used to direct SSEA1 for detection of MH-15 teratocarcinoma xenografts [14]. In
this study, fluorescence did concentrate in the tumor, but significant background from the conjugate was observed in the
kidneys and bladder. The NIR dye, Cy5.5, appeared to yield
the best signal-to-background. Finally, minibodies directed
against the extra-domain B of fibronectin and conjugated to
Cy7 have been used to successfully image atherosclerotic
plaques in a mouse model [15].
Although antibody conjugates have been successfully
used, they have several undesirable features, primarily due to
the size of the antibody. Larger molecules, such as antibodies, can elicit an adverse immune response from the host animal, and their long half-life in the blood results in high background fluorescence and long clearance times [16] and [17].
In addition, large biomolecules are often taken up preferentially by the liver, precluding imaging of liver-proximal organs [18]. Finally, for the contrast agent to effectively penetrate to the target site, it must diffuse from the vasculature to
the site of the pathology; larger molecules show very poor diffusion characteristics which may prevent them from reaching
the target site [19].
Tumor surface proteins
Tumor surface proteins offer diverse possibilities for targeting
of optical probes. An excellent example is a receptor-binding
ligand. Growth factors are a popular choice for optical imaging agents because, in addition to high-affinity targeting, the
ligand and its fluorescent label are often internalized by the
normal endocytic pathway, amplifying the signal in the tumor
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cells. Fluorochrome-labeled epidermal growth factor (EGF)
has been a versatile tumor imaging agent because the epidermal growth factor receptor (EGFR) is overexpressed on the
surface of many types of tumor cells [20], [21], [22], [23], and
[24]. In a study measuring the diffusion of small molecules
across the extracellular space in rat brains, Thorne et al. [25]
showed that EGF labeled with Oregon green 514 could be
used as a reporter. Ke et al. [26] used Cy5.5-labeled EGF to
target human breast tumor cells implanted in mice. The EGFCy5.5 accumulated specifically in the tumors and uptake was
blocked by pretreatment of animals with C225 anti-EGFR
monoclonal antibody (cetuximab).
Similarly, we have demonstrated the utility of EGF labeled
with IRDye 800CW for analysis of orthotopic prostate tumors
in mice [27] and [28]. IRDye 800CW EGF accumulated specifically in the tumors, and metastatic spread of the primary
orthotopic tumor to the paraaortic lymph nodes was detected.
EGF is known to stimulate tumor growth, and this is an important concern for its use as an imaging agent. Comparison of tumors excised from animals injected with labeled EGF only at
the study endpoint to tumors excised from mice that had been
injected at weekly intervals over a 6 week period demonstrated
no stimulation of tumor growth by the fluorochrome-conjugated ligand used in this longitudinal study [27].
Endostatin, a 20-kDa fragment of collagen XVIII, is a potent inhibitor of angiogenesis. Using Cy5.5-labeled endostatin,
Citrin et al. [29] were able to demonstrate that the labeled optical agent bound specifically to tumor xenografts in C57BL
mice, suggesting that the antiangiogenic effect of endostatin
is due to its action directly on the tumor cells rather than to
a general antiangiogenic effect. The Cy5.5-endostatin bound
specifically to the tumor and the signal persisted for up to 7
days postintraperitoneal injection [29].
Apoptosis plays an important role in a number of disease
pathologies, particularly cancer. One of the earliest markers
of apoptosis is the externalization of phosphatidylserine. Annexin V, a 36-kDa protein, exhibits high affinity for phosphatidylserine and has been used to detect apoptosis in vivo. Petrovsky et al. [30] and Ntziachristos et al. [31] demonstrated the
utility of Cy5.5-labeled annexin V for detection of apoptosis
in a mouse tumor model. This marker may be useful in studying the antiproliferative effects of chemotherapeutic agents on
a variety of cancers.
Somatostatin receptors and their ligands have been used
as a targeting system for tumor imaging and radiotherapy of
cancer for over 15 years. Radiolabeled synthetic analogues of
somatostatin have been used to successfully image gastric or
pancreatic tumors and small-cell lung cancer (SCLC) [32] and
[33]. SCLC is a major cause of death in western countries.
The substitution of fluorochrome-tagged somatostatin and
several analogues has enabled imaging of human H69 SCLC
tumor xenografts in mice using fiber-optic spectrofluorimetry.
Thus, near-infrared-conjugated peptides may have significant
clinical impact on tumor detection by endoscopy, mammography, and intraoperative imaging.
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Peptides and small molecules

Developing an optical imaging agent

Because of their small size, convenience of handling, and attractive pharmacokinetic properties, peptides are useful agents
for in vivo imaging. Peptides targeting integrins, a family of
cell surface receptors that broadly regulate tumor growth, metastasis, and angiogenesis, have been successful agents for imaging neovascular density [34], [35], [36], [37], [38], [39],
[40], and [41]. Chen et al. [37] and Achilefu et al. [41] used an
NIR peptide conjugate, arginine-glycine-aspartic acid (RGD),
targeting αvβ3 integrin, to detect and image tumor xenografts
and to monitor angiogenesis. Tumor uptake of the Cy5.5 RGD
peptide was specific and could be blocked by preinjection
with unlabeled RGD. Houston et al. [42] used an RGD peptide
doubly labeled with 111indium and IRDye 800CW to directly
compare NIR optical imaging with scintigraphy. The authors
found the signal-to-background ratio significantly higher for
IRDye 800CW than for the radioactive label.
In general, small molecules and peptide imaging agents
clear the system quickly, translating to a reduction in fluorescent background when imaging. In all cases described
above, the agents cleared through the kidneys without pooling in the liver. The small size also greatly reduces the possibility of an adverse immune response. Finally, fluorochromelabeled small molecules and peptides penetrate to the target
efficiently because of their increased ability to diffuse from
the vasculature.

Below, we will discuss some of the critical parameters involved in developing, validating, and using an optical imaging agent. We present an overview of the process as it
applies to tumor imaging, using as an example the IRDye
800CW EGF imaging agent that we recently developed [27]
and [28]. Again, although we use this agent as an example,
the principles described will be applicable to any dye-conjugate optical agent.

Activatable probes
The last category of fluorescent agents, activatable probes
or “molecular beacons” [43] and [44], specifically yield a
fluorescent signal only when activated by an enzyme target. Most activatable probes are protease substrates. Protease levels are elevated in the extracellular space of many tumors, where they play roles in invasion and metastasis [45],
[46], [47], [48], and [49] and present a physically accessible target. Typically, these probes contain multiple NIR fluorochromes coupled to peptide sequences that can be cleaved
by the protease. The proximity of the fluorochromes to each
other results in quenching that is relieved upon cleavage by
the target protease to generate a fluorescent signal. Use of
fluorochrome/quencher pairs separated by the peptide target
sequence has also been reported.
Proteases that have been targeted by activatable probes include cathepsins, matrix metalloproteinases (MMPs), prostate-specific antigen, thrombin, caspase-3, and interleukin-1β
converting enzyme [50]. An example of the signal sensitivity
that can be achieved using these agents is the visualization of
MMP-2 activity [50], [51], and [52]. In vitro, the authors observed an 850% increase in NIR fluorescence intensity when
the probe was cleaved and specific activation could be blocked
by MMP-2 inhibitors. MMP-2-positive human fibrosarcomas were visualized and differentiated from MMP-2-negative
mammary adenocarcinomas using this probe.

Conjugating probes with NIR dyes
Development of an optical targeting agent begins with covalent attachment of an NIR dye to the targeting compound.
Many dyes are available with an N-hydroxysuccinimidyl
(NHS) ester, which is activated for simple one-step coupling
to free amines. NHS esterified NIR dyes may be purchased in
bulk or in prepackaged labeling kits. Methods for removal of
unreacted dye may include HPLC, FPLC, or dialysis. Purification will be dictated by the molecular weight and chemical
properties of the conjugates.
For in vivo imaging applications, the dye/protein ratio of
the conjugate may affect biological or biochemical activity of
the protein, signal-to-background ratio, clearance, and biodistribution [52]. The optimal ratio of coupling is unique to each
targeting agent. For example, Ntziachristos et al. [31] found
that annexin V labeled with Cy5.5 at a dye/protein ratio of 1
retained its ability to bind phosphatidylserine on the surface of
cells induced for apoptosis, while the same molecule labeled
at a dye/protein ratio of 2.4 had lost its binding capability.
If the optical imaging agent is based on a commercially
available reagent such as an antibody or receptor ligand, differences in preparation and purification may impact performance. We conjugated IRDye 800CW to human recombinant
EGF from five different commercial sources, at equivalent
dye/protein ratios, and evaluated relative signal intensity by
In-Cell Western (ICW) [28]. As shown in Figure 2, there were
considerable differences in the amounts of EGF bound to the
cells. Variations in signal strength measured in this fashion
have the potential to predict probe performance in vivo as we
have demonstrated [28].
Testing the performance and specificity of an optical imaging agent in vitro
Validation of targeting agent efficacy and specificity in vitro
is an important prelude to animal studies. Specificity can be
demonstrated on cells in culture or in suspension by blocking the target with an antibody or by competition with the unlabeled agent. In targeting somatostatin receptors, Becker et
al. [53] used a flow cytometric assay to quantify binding of
the agent. As mentioned above, Ntziachristos et al. [31] used
whole-cell competition assays to demonstrate both probe specificity and binding affinity. Another group used a radioactive
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In the United States, these regulations are described in a document compiled by the National Institutes of Health Organization for Lab Animal Welfare, available at
http://grants.nih.gov/grants/olaw/GuideBook.pdf.
Considerations for tumor model selection

Figure 2. Binding activity of recombinant EGF from different commercial sources. EGF from five sources was conjugated to IRDye
800CW at similar dye/protein ratios and each was evaluated for its
ability to bind confluent A431 monolayers by In-Cell Western as we
have previously described [27].

displacement assay [54]. 125I-labeled echistatin, an integrinbinding ligand, was added to integrin-expressing cell cultures
and allowed to bind. The degree of displacement of the radioactive echistatin by Cy7-labeled RGD peptide was used as a
measure of specificity and binding affinity.
We have used the ICW or cytoblot to evaluate IRDye
800CW EGF for binding and specificity prior to actual testing in mice [27] and [55]. In this assay, PC3M-LN4 and
22Rv1 human prostate adenocarcinoma cells were cultured
in microtiter plates and treated with serial dilutions of labeled EGF (Figure 3A) to verify high affinity binding of
EGFR-targeted dye relative to the low binding of free dye
alone (Figure 3B). Specificity was then established in two
ways: by blocking access of EGF to its receptor with the
anti-EGFR monoclonal antibody C225 (also known as cetuximab or Erbitux, Figure 3C) and by competition with unlabeled EGF (Figure 3D). Fluorescence of the microplate
was quantified by NIR imaging, and a DNA stain was used
to normalize variations in cell number.
Characterization of the targeting agent in a cell-based assay can simplify probe development. While success in a cellbased assay format does not guarantee performance in vivo,
failure in this assay is generally predictive of failure in the
animal. In addition, the competition assays developed may
subsequently be useful for demonstrating specificity in animal experiments.
Animal care and use
All research animals must be handled according to protocols
that comply with the animal care and use regulations of the
country and institution where the research will be performed.

An ideal tumor model system exhibits minimal background
interference. Although much of the autofluorescence in the
animal is ameliorated by imaging at NIR wavelengths, some
anatomic regions inherently maintain higher fluorescent signals. For example, natural fluorescence from compounds in
the animal’s diet accumulates and can be visualized in the abdominal cavity. Organs involved in clearance of the dye, such
as the liver and kidney, may also accumulate signal. Tumors
arising in areas remote from these organs are detected with
less ambiguity and higher sensitivity. In the case of subcutaneous xenografts, the placement of transplanted tissue in the
flank, shoulder, or leg of the animal can minimize these interfering factors.
The model system selected will depend on the aims of the
study. Transgenic, chemically induced, and spontaneously
arising mouse models that recapitulate many aspects of the
genesis, progression, and clinical course of human cancers are
available. The National Cancer Institute of the United States
has organized a Cancer Models Database (caMOD) to facilitate identification of appropriate models for cancer experimental design (http://0-cancermodels.nci.nih.gov.library.unl.
edu:80/camod/login.do;jsessionid=D8B27DC9B409DA8CC3
7CE04150EBAABB).
Three strains of immunodeficient mice are commonly used
in tumorigenesis and metastasis research with human cell
lines: nude, SCID, and Rag1. The nude mouse (athymic; nu/
nu) has a disruption in the Foxn1 gene, resulting in an absent
or deteriorated thymus gland, diminished T cell numbers, and
a severely impaired cellular immune system [56]. The resultant hairless phenotype also makes the nude mouse ideal for
optical imaging, since animal hair blocks and scatters light.
Over time, these animals may regain partial cellular immune
function so nude mice may not be the best host for longer-term
studies of tumor biology. SCID (severe combined immunodeficiency) mice lack both mature T and B lymphocytes [57]
and are an effective alternative to nude mice in cases where
the partial immune system of the nude mouse presents a problem. The Rag1 mouse also lacks T and B lymphocytes and is
not able to undergo V(D)J recombination. Thus, it fails to produce T-cell receptors and immunoglobulin molecules for antigen identification [58], [59] and [60]. All three mouse models bear phenotypic and background strain characteristics that
may impact a research project.
Immunocompromised mice require specific-pathogen-free
handling to avoid introducing infections. Institutional training
is obligatory and includes instruction in the use of infection
barriers, sterilized food, water, and bedding, disinfected imaging surfaces, gloved handling, and aseptic technique.
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Figure 3. Binding specificity of IRDye 800CW EGF for cultured PC3M-LN4 and 22Rv1 cells. Monolayer cells in 96-well microplates were incubated with increasing concentrations of IRDye 800CW EGF (A) or unconjugated nonreactive IRDye 800CW (B) and normalized with TOPRO-3 staining. To demonstrate EGF receptor-targeting specificity, cells were incubated with 70 nM IRDye 800CW EGF in the presence of increasing concentrations of either C225 blocking antibody (C) or unlabeled EGF (D). The 800-nm signal, normalized to the 700-nm control, is
plotted as the mean ± SD of three replicate wells [27]. This figure is reproduced with permission from the American Journal of Pathology.

Reducing optical interference for tumor imaging
Chlorophyll, which is often present in animal chow, absorbs
at 655 and 411 nm and fluoresces at 673 nm, producing strong
signal in the abdominal cavity. For optimal fluorescent imaging performance, purified food formulations that do not contain plant products may be used. Fasting of the animal prior to
imaging has been used in some studies and requires prior approval from the institutional committee governing animal care.
The hairless phenotype of the nude mouse makes it an
ideal choice for NIR optical imaging, but this model may not
always be appropriate for the research objectives. Thus, hair
removal in the imaging region may be important for optimal signal detection. Animal hair interferes with imaging by
blocking, absorbing, and scattering light. We evaluated this by
implanting a tube containing IRDye 800CW in the chest cavity of a deceased SCID mouse and imaging the animal before
and after shaving. Following shaving, fluorescent signal increased by >50% (data not shown). An additional 12% signal
was detected when the animal was treated with a depilatory
cream (Nair, Church and Dwight Co., Inc.) presumably due to
the removal of hair stubble.
Establishing tumors in the animal
For assays of tumorigenic and metastatic potential using cultured human cells, cells or tissue may be implanted in animals

subcutaneously, intravenously, intraperitonally, or orthotopically (i.e., prostate cells implanted in mouse prostate). These
assays are called xenografts, since they involve transplantation of cells, tissue, or organs from one species to another.
Depending on the aggressiveness of the cell line, we have
established subcutaneous xenografts in mice by injection of
0.5–1 × 106 cells in ≈100 μL cell suspension. Tumors become
palpable within 7–10 days. Orthotopic injections require
fewer cells (we have used 1 × 105 cells) and reduced injection
volume (10 μL), as the prostate is small. Tumors form in 2–3
weeks and metastasize within ≈6 weeks [27] and [28].
Probe dosage and administration
Tumor type may dictate the optical imaging agent selected
and its optimal parameters for use. For example, A431 epidermoid carcinoma cells express EGFR at a much higher level
than normal cells. However, HeLa ovarian carcinoma cells
have low expression of EGFR. If IRDye 800CW EGF is used
as an optical probe for both of these cell types, binding of the
labeled ligand would be expected to vary dramatically.
An optimal dosage of the imaging agent will afford the
best signal-to-background, clearance, and imaging results. Excessively high doses will clear poorly, while a low dose may
not saturate tumor uptake. Figure 4 illustrates a dose response
to increasing concentrations of an optical agent. Although
background increases with the amount of probe administered,
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Figure 4. Dose response for an IRDye 800CW-conjugated optical imaging agent targeting tumors in nude mice. Animals were injected with 1×
phosphate-buffered saline as a negative control (A), or with 2.5 nmol (B), 5.0 nmol (C), and 10 nmol (D) of a tumor-targeted IRDye 800CW
conjugate. Images were acquired 24 h postinjection.

the signal is also greater at the highest dose. The quantified
signal within the tumor, normalized to the mean background
in several irrelevant surrounding regions, allowed us to determine that the optimal specific signal occurred at the two highest doses.
The route of targeting agent administration can affect its
specific uptake and nonspecific clearance. Intravenous injection via the tail vein or supraorbital cavity leads to rapid systemic dispersion (Figure 5B). This method is appropriate for
targeted contrast agents that bind a ubiquitous surface receptor present at a greater concentration on tumor cells. Uptake
by the tumor cells is within the time window of agent clearance and potential background from prolonged exposure to
the probe is minimized. Performance of an agent that functions by incorporation into bone, however, may be enhanced
by intraperitoneal injections, which prolong exposure through
slower dispersion (Figure 5A).

Evaluation of dye and optical agent clearance
Performing initial imaging time courses following injection
of the chosen targeting agent will establish the optimal time
point for sensitive tumor analysis. First, the time course analysis begins with the unconjugated fluorochrome chosen for
optical imaging, which should not be appreciably retained in
the animal. An example of measurement of the clearance of
IRDye 800CW is shown in Figure 6. Other dyes may have
different clearance characteristics. Second, a time course of
agent clearance from non-tumor-bearing control animals using
the intended dose for tumor imaging will yield a blueprint for
whole-body nonspecific background to assist interpretation of
tumor images. Figure 7 shows the results of a clearance experiment with IRDye 800CW EGF in a tumor-negative mouse.
Finally, once it has been determined that the probe does
not accumulate nonspecifically, the time course is repeated

Figure 5. Impact of administration site on optical imaging agent dispersion in mice. Images were acquired approximately 15 min following intraperitoneal (A) or intravenous (B) injection of equivalent amounts of an optical imaging agent into a nude mouse.
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Figure 6. Clearance kinetics of unconjugated IRDye 800CW. A SCID mouse was injected with 1 nmol of IRDye 800CW intravenously and
monitored over time for complete clearance of the dye. Imaging times postinjection are indicated on each individual image. Pseudocolored fluorescence is superimposed on the white light image of the mouse to illustrate rapid dispersion of the dye followed by complete clearance.

Figure 7. Time course for clearance of IRDye 800CW EGF from a non-tumor-bearing mouse. A SCID mouse was injected with 1 nmol of
the EGF-conjugated optical agent intravenously and imaged at the indicated time points over a 24-h period. Analysis of the abdominal region
showed that >90% of the fluorescence disappeared in 24 h, and by 48 h (not shown) the probe had cleared completely.

with tumor-bearing animals to determine the imaging time at
which the signal-to-background is greatest in the tumor. For
IRDye 800CW EGF, mice bearing PC3M-LN4 subcutaneous
xenografts were imaged over a 3-day period. By 24 h, most
of the initial fluorescence was gone from the nontumor areas
(Figure 8). However, signal-to-background continued to increase beyond this time point. Optimizing the time of imaging
maximizes sensitivity for challenging applications such as detecting metastatic spread of a tumor.
Confirming probe specificity in vivo
Clearance studies and optimization of timing will minimize
nonspecific fluorescence, but imaging artifacts may be misin-

terpreted nonetheless. For example, an apparent tumor detected
in the liver upon targeting with an antibody probe that pooled in
the liver should be confirmed by a competition test. One method
is to preinject tumor-bearing animals with an excess (for example, 100-fold) of the unlabeled form of the optical agent. The
labeled agent is injected shortly thereafter. Probe specificity is
reflected as a decrease in the total fluorescence signal in animals that were preinjected with the unlabeled agent. Specificity
of Cy5.5-labeled EGF was demonstrated in this way by Ke et
al. [26]. Even if differential signal is not readily detected in intact animals, imaging analysis of excised whole and sectioned
tumors may reveal the competition.
We used this approach to assess specificity of IRDye
800CW EGF imaging in prostate tumors [27]. Mice bearing
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Figure 8. Time course for accumulation of IRDye 800CW EGF in a subcutaneous tumor. Images of a nude mouse were collected prior to injection (A) or at 20 min (B), 24 h (C), 48 h (D), and 72 h (E) following intravenous injection of the animal with 1 nmol of IRDye 800CW EGF.

either PC3M-LN4 subcutaneous or orthotopic tumors were
injected with IRDye 800CW EGF; some animals were preinjected with C225 anti-EGFR monoclonal antibody. When
we injected tumor-bearing animals with the probe and subsequently performed fluorescence imaging of tumor sections,
IRDye 800CW EGF was clearly visible not only in the primary tumors but also in lymph nodes extracted from the animals (Figure 9). Tumor-bearing animals that were preinjected

with C225 exhibited a 33–49% decrease in fluorescent signal,
indicating that binding of the labeled ligand was specific for
EGFR.
An alternative approach to demonstrating specific signal
is to quantify targeting agent uptake by both tumor and nontumor tissue. For examining integrin-binding agents, Becker
et al. [53] used an RGD peptide doubly labeled with 125I and
an indocarbocyanine dye. Radioactive content of the tumor,

Figure 9. Demonstration of specific tumor targeting in vivo for the IRDye 800CW EGF optical imaging agent. Tumors and lymph nodes
were excised from animals bearing either subcutaneous (A) or orthotopic (B) prostate tumors, as indicated, injected intravenously with IRDye
800CW EGF or preinjected with C225 anti-EGFR monoclonal antibody prior to dosing with IRDye 800CW EGF. The corresponding table
presents IRDye 800CW EGF fluorescence signal per area tissue for vehicle control, optical agent only, and C225 competition for each tumor
type (subcutaneous and orthotopic) and lymph nodes from the orthotopic tumor model (C).
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heart, liver, kidneys, and brain was quantified following imaging of the tumor. Thus, the authors were able to express
the uptake of the probe as the percentage of injected dose per
gram of tissue. This approach may also be useful for characterization of metabolic probes, for which high doses of unlabeled competitor may be toxic.
Conclusions
Fluorochrome-labeled molecular probes are valuable tools for
noninvasive longitudinal study of tumorigenesis and metastasis, preclinical studies of the effects of therapeutic agents, and
pharmacokinetic and pharmacodynamic studies of drug–target
interactions. Because of this, these probes have significant potential for translation to human clinical use.
Several applications may expand the clinical utility of
fluorochrome-labeled probes. For example, accurate definition of tumor margins is crucial to the therapeutic outcome
of many surgical oncology procedures. A multimodal imaging agent consisting of a magnetic iron oxide nanoparticle and
Cy5.5 has been used as a preoperative nuclear magnetic resonance contrast agent and intraoperative optical probe to define
the tumor margins in a rat gliosarcoma model [61]. Similar
intraoperative imaging technology is being developed in the
laboratory of Frangioni [62]. These procedures would allow
a surgeon to identify and locate the tumor mass by MRI and
subsequently remove the tumor accurately with visual guidance from an intraoperative near-infrared fluorescent imager.
Photodynamic therapy is an application that has been used
in oncology for over 2 decades [9]. A photosensitizing agent
delivered to malignant tissue is exposed to light, generating
cytotoxic singlet oxygen. The result is cell death through the
induction of apoptosis, microvascular damage, and antitumor
immune response. The major class of dyes used for this approach is phthalocyanines such as IRDye 700DX [8]. NIR
dyes conjugated to antitumor therapeutics such as Erbitux
(anti-EGFR monoclonal antibody) may have similar clinical
appeal for simultaneous treatment and monitoring of anticancer therapy [63].
Imaging based on expression of luciferase or a fluorescent
protein such as GFP has facilitated examination of intracellular signaling events in vivo. Hybrid gene constructs in which
either the luciferase or the GFP gene is placed under control
of an inducible promoter responsive to a signaling pathway of
interest have been used to directly assess the effects of antitumor agents on the gene regulation in vivo. A similar reporter
system that directly images β-galactosidase activity on a farred substrate has been recently reported [64]. This fluorescent
reporter system could provide a means for creating hybrid expression units to examine in vivo gene expression and regulation of a number of important pathways in cancer.
NIR-based imaging instrument technologies designed for
human clinical use are in various stages of development [62],
[65] and [66]. Combined with new NIR-labeled biomarkers, these will expand the clinical options available for can-
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cer management in the near future. Several excellent reviews
describe the use of targeted markers in animal studies [7] and
[67].
In this review we have discussed the basic validation of
fluorochrome-labeled molecular probes. Although near-infrared optical excitation sources provide deeper tissue penetration, they are not great enough to provide unlimited application for human clinical use. Near-infrared imaging agents may
be limited to accessible tissues such as breast tumors or to intraoperative applications, endoscopy, and photodynamic therapy. However, these applications represent significant benefits
for research, diagnosis, and treatment. Continued technological innovation in imaging instrumentation, biomarker discovery, and labeling chemistries will foster the clinical use of fluorescent optical imaging.
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